Session B21: RESEARCH STUDIES IN INTERVENTIONAL PULMONARY AND PLEURAL DISEASE
TIME: 9:15 AM - 11:15 AM
Outcomes of Bronchoscopic Lung Volume Reduction in Patients With Static and Dynamic Hyperinflation
A. B. Karanam, M. Reeves, J. Thomas, G. J. Criner
Session B47: LUNG TRANSPLANT
TIME: 11:30 AM – 1:15 PM
Navigating Airway Challenges After Lung Transplantation
Z. Dhanani, G. J. Criner, F. Anjum
Preoperative Anemia as a Risk Factor for Post Operative Outcomes in Patients Undergoing Lung Transplant
J. Galvis, T. A. Ho, O. Schanz, T. Russeth, H. Zhao, J. Armstrong, J. Mamary
The Prevalence and Evaluation of Anemia in Lung Transplant Recipients: A Single Center Experience
T. A. Ho, J. Galvis, M. Goulet, T. Joshi, H. Zhao, J. Armstrong, A. J. Mamary
Session B48: NEW TREATMENTS IN DIFFUSE PARENCHYMAL LUNG DISEASE
TIME: 11:30 AM – 1:15 PM
Pulmonary Vasodilator Therapy in Idiopathic Pulmonary Fibrosis Associated Pulmonary Hypertension
R. Strock, O. A. Schanz, P. Rali, G. J. Criner, S. Gayen
Session B50: EMERGING RESEARCH IN ALPHA-1-ANTITRYPSIN DEFICIENCY
TIME: 11:30 AM – 1:15 PM
Effectiveness of Bronchoscopic Lung Volume Reduction With Zephyr Endobronchial Valves in Alpha-1 Antitrypsin Deficient Chronic Obstructive Pulmonary Disease Patients Versus Chronic Obstructive Pulmonary Disease Patients Without Alpha-1 Antitrypsin Deficiency: A Matched Case-control Study
M. Nicholson, G. J. Criner
Session B52: EVIDENCE FOR THERAPEUTIC STRATEGIES IN COPD: FROM ESTABLISHED TO EMERGING
TIME: 11:30 AM – 1:15 PM
Impact of Biologics in Patients With COPD and ACOS: A Real-world, Single-center Review of Factors Associated With Greater Reduction in Exacerbation Frequency
S. Dachert, T. A. Ho, I. Albaba, S. Ansari, N. Provenzano, J. Halicki, G. J. Criner
Ensifentrine Added on to LABA/ICS Therapy Improved Lung Function and Reduced Exacerbations in Symptomatic Subjects With Moderate-to-Severe COPD
N. Marchetti, R. Kalhan, M. T. Dransfield, A. Anzueto, T. Rheault, D. Reyner, T. Bengtsson, K. Rickard
Targeted Lung Denervation in COPD: 2-year Follow-up of the Airflow-3 Open-label Treatment Cohort
G. J. Criner, F. C. Sciurba, D.-J. Slebos, S. P. Bhatt, C. Ghattas, B. Petkovich, J. De Cardenas, C. R. Lamb, R. D. Sue, P. L. Shah
Session B59: DEFINING DISPARITIES IN PULMONARY VASCULAR DISEASES
TIME: 11:30 AM – 1:15 PM
Disparity in Pulmonary Embolism Outcomes Amongst Asians
A. Mittal, S. Li2, T. A. Ho, M. Yaqoob, P. Rali
Session B60: CYANOTIC PACIFIC BLUE: GROUP 3 PH AND HYPOXIC LUNG DISEASE
TIME: 11:30 AM – 1:15 PM
Prognostic Limitations for Who Group 3 Pulmonary Hypertension Patients - A Retrospective Study
M. J. Bittner, J. M. Pescatore, S. E. Weaver, S. Gayen
Clinical Significance of Updated Pulmonary Hypertension Guidelines on Combined Pulmonary Fibrosis and Emphysema (CPFE)
J. Moore, P. Rali, S. Gayen
New European Society of Cardiology Definition of Severe Pulmonary Hypertension Predicts Mortality in Patients With Idiopathic Pulmonary Fibrosis
A. Kurtzman, P. Rali, G. J. Criner, S. Gayen
Pulmonary Vasodilatory Therapy in Patients With Chronic Obstructive Pulmonary Disease-mediated Pulmonary Hypertension
A. Chung, P. Rali, G. J. Criner, S. Gayen
ILD/CPFE With Severe WHO Group III PH Patients Referred to Transplant Center for Evaluation: An Observational Study
J. M. Pescatore, M. Bitter, S. E. Weaver
Effect of Updated European Society of Cardiology Pulmonary Hypertension Diagnostic Criteria on Lung Transplantation Waitlist Outcomes in Hypersensitivity Pneumonitis Patients Listed for Lung Transplantation
M. Nicholson, Z. Dhanani, S. Gayen
Effect of Pulmonary Vasodilator Therapy on Survival and Functional Outcomes in Patient With Combined Pulmonary Fibrosis and Emphysema and Pulmonary Hypertension
O. A. Schanz, I. Tsai, J. Moore, T. Joshi, A. Chung, R. Strock, A. Kurtzman, T. Russeth, K. Johnson, J. Galvis, S. Gayen
Session B61: THE NEED FOR SPEED: ARTIFICIAL INTELLIGENCE IN PVD
TIME: 11:30 AM – 1:15 PM
AI-driven PE Detection and RV/LV Ratio Measurement: A Preliminary Validation Study
Z. Dhanani, K. U. Lio, T. Joshi, P. Rali
Real World Assessment of Artificial Intelligence for Pulmonary Embolism Detection and Risk Stratification
S. Pettigrew, J. Nathan, K. Maruti, G. Cohen, G. J. Criner, P. Rali
Session B70: COPD IN THE SPOTLIGHT: INSIGHTS INTO DISEASE PATHOGENESIS
TIME: 11:30 AM – 1:15 PM
S100A8-MCM3 Axis in Alveolar Type II Cells in Emphysema
K. Bahmed, C. Lin, S. Bolla, N. Marchetti, G. J. Criner, B. Kosmider
Session B80-2: ABNORMALITIES IN STRUCTURE AND FUNCTION IN COPD
TIME: 11:30 AM – 1:15 PM
Change in Pulmonary Artery: Aorta Ratio (PA:A) in Patients Undergoing Bronchoscopic Lung Volume Reduction Surgery (BLVR) Vs Lung Volume Reduction Surgery (LVRS)
S. Ansari, S. Dachert, S. Gayen, J. Thomas, H. Zhao, C. Dass, G. J. Criner
Predictors of Dynamic Hyperinflation in Advanced Chronic Obstructive Pulmonary Disease
A. B. Karanam, J. Thomas, G. J. Criner
Back to top >